| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33168c56094caae6de7b1a144448fe54 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10323
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-13045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10345
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-859 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 |
| filingDate |
1998-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1999-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0959136-A1 |
| titleOfInvention |
Targeted delivery through a cationic amino acid transporter |
| abstract |
The invention relates to the targeted delivery of substancesnto cells. The invention provides a virus-like particle orngene delivery vehicle provided with a ligand capable ofnbinding to a human amino acid transporter. Provided are fornexample ligands that can bind to the human transporter ofncationic L-amino acids (hCAT1). Such hCAT1 binding moleculesnfind applications in the design of vector systems for entryninto human or primate cells. Preferred are retroviralnenvelope molecules, which - when incorporated in a virusnparticle - can infect hCAT1 positive cells at highnfrequencies. Also within the scope of the invention arenmethods for the design of such hCAT1 binding molecules. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007016164-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007016164-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7226741-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7498138-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7670782-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02081504-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0217948-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0217948-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02081504-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6455314-B1 |
| priorityDate |
1998-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |